Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma

Exclusion Criteria

• •Patients with recurrent glioma who have previously undergone surgery or radiotherapy and chemotherapy
• •Glioma of the spinal cord
• •ECOG score\> 3 points
• •Severe mental symptoms; uncontrollable status epilepticus
• •Patients with malignant tumors in other parts
• •The patient has an active bacterial, viral or fungal infection (≥ Grade 2 NCI-CTC, 4th edition)
• •The patient has severe liver and kidney dysfunction, HIV infection, HCV infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases that the researcher thinks cannot be included in the group
• •Pregnant and lactating women. Women of childbearing age must have a negative pregnancy test within 7 days before joining the group
• •Drug abuse, clinical, psychological or social factors affect informed consent or research implementation
• •Any uncertain factors that affect the safety or compliance of patients